x
Filter:
Filters applied
- ACMG Statements and Guidelines
- Palomaki, Glenn ERemove Palomaki, Glenn E filter
- Popovich, Bradley WRemove Popovich, Bradley W filter
Author
- Grody, Wayne W2
- Richards, C Sue2
- Watson, Michael S2
- Bellissimo, Daniel B1
- Bradley, Linda A1
- Cutting, Garry R1
- Desnick, Robert J1
- Driscoll, Deborah A1
- Feldman, Gerald1
- Klinger, Katherine1
- Matteson, Carla J1
- Mennuti, Michael1
- Pratt, Victoria M1
- Prior, Thomas W1
- Rohlfs, Elizabeth M1
- Spector, Elaine B1
- Strom, Charles M1
- Witt, David R1
- Wolff, Daynna J1
ACMG Statements and Guidelines
These online statements and guidelines are definitive and may be cited using the digital object identifier (DOI). These recommendations are designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical genetics services; they should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Please refer to the leading disclaimer in each document for more information.
2 Results
- ACMG Standards and GuidelinesOpen Archive
Technical standards and guidelines: Venous thromboembolism (Factor V Leiden and prothrombin 20210G>A testing): A disease-specific supplement to the standards and guidelines for clinical genetics laboratories
Genetics in MedicineVol. 7Issue 6p444–453Published in issue: July, 2005- Elaine B. Spector
- Wayne W. Grody
- Carla J. Matteson
- Glenn E. Palomaki
- Daniel B. Bellissimo
- Daynna J. Wolff
- and others
Cited in Scopus: 34Disclaimer: These standards and guidelines are designed primarily as an educational resource for clinical laboratory geneticists to help them provide quality clinical laboratory genetic services. Adherence to this statement does not necessarily ensure a successful medical outcome. These standards and guidelines should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinical molecular geneticist should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen. - ACMG Policy StatementOpen Archive
Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel
Genetics in MedicineVol. 6Issue 5p387–391Published in issue: September, 2004- Michael S. Watson
- Garry R. Cutting
- Robert J. Desnick
- Deborah A. Driscoll
- Katherine Klinger
- Michael Mennuti
- and others
Cited in Scopus: 366An erratum to this article is available online at https://doi.org/10.1038/gim200480 .
